US Stock MarketDetailed Quotes

ASMB Assembly Biosciences

Watchlist
  • 13.020
  • +0.810+6.63%
Close Feb 14 16:00 ET
  • 13.020
  • 0.0000.00%
Post 16:00 ET
82.76MMarket Cap-1.89P/E (TTM)

About Assembly Biosciences Company

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Company Profile

SymbolASMB
Company NameAssembly Biosciences
Listing DateDec 17, 2010
Issue Price6.00
Founded2005
CEOMr. Jason A. Okazaki
MarketNASDAQ
Employees65
Fiscal Year Ends12-31
AddressTwo Tower Place,7th floor
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-833-509-4583

Company Executives

  • Name
  • Position
  • Salary
  • Jason A. Okazaki
  • Director, President, Chief Executive Officer and Principal Financial Officer
  • 1.37M
  • William E. Delaney, PhD
  • Chief Scientific Officer
  • 811.82K
  • Anuj Gaggar
  • Chief Medical Officer
  • --
  • Nicole S White
  • Chief Manufacturing Officer
  • 705.51K
  • Jeanette M. Bjorkquist
  • Executive Director, Accounting and Treasury and Principal Accounting Officer
  • --
  • William R. Ringo, Jr
  • Chairman of the Board
  • 122.08K
  • Dr. Tomas Cihlar, PhD
  • Director
  • --
  • Dr. John G. McHutchison, A.O.,M.D.
  • Director
  • 64.58K
  • Robert D. Cook, II
  • Director
  • --
  • Dr. Lisa R. Johnson-Pratt
  • Independent Director
  • 64.58K
  • Anthony E. Altig
  • Independent Director
  • 79.58K
  • Dr. Susan Mahony, M.B.A.,PhD
  • Independent Director
  • 74.58K
  • Dr. Michael Houghton
  • Independent Director
  • 59.58K
  • Gina Consylman
  • Independent Director
  • 72.08K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More